

Serial No. : 09/590,447  
Filed : June 9, 2000


#### REMARKS

Applicants that the Examiner for the helpful suggestions contained in the January 29, 2003 Office Action, and for indicating that the claims, amended as above, are allowable. The claim Amendments made herein render moot the rejections pursuant to 35 USC 112(1) and 35 USC 112(2)

Therefore the claims appear to be in condition for allowance. Please use Deposit Account 01-0885 for the payment of the extension fees or any other fees due in connection with the current response.

Respectfully submitted, ✓

Dated: 6/30/03

By:   
Carlos A. Fisher  
Registration No. 36,510  
Attorney of Record

Allergan, Inc.  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714-246-4920  
Facsimile: 714-246-4249



COPY

MAIL STOP AMENDMENT-FEE

Rec'd in USPTO/PCT Office. Date Stamp and Return Card.

Date: 6/30/2003

Serial No.: 09/590,447; Conf. No. 1446

Title: METHODS FOR MODULATING FXR RECEPTOR.

Dkt. No.: 17302 (HL)

Enclosed Are:

- |  |  |
|--|--|
| <input type="checkbox"/> Specification # _____, Claims # _____, and Abstract # _____ | <input type="checkbox"/> Declaration, Power of Attorney                  |
| <input type="checkbox"/> Drawings (_____ sheets)<br>_____ Formal _____ Informal      | <input type="checkbox"/> Assignment & Cover Sheet                        |
| <input type="checkbox"/> Info. Disc. Statement                                       | <input checked="" type="checkbox"/> Amendment (Final) (# pgs. <u>7</u> ) |
| <input type="checkbox"/> Priority Documents # _____                                  | <input checked="" type="checkbox"/> Certificate of Mailing               |
| <input type="checkbox"/> PTO 1449 W/References                                       | <input type="checkbox"/> Issue Fee Transmittal                           |
| <input type="checkbox"/> PCT Request (# pgs. _____)                                  | <input type="checkbox"/> Transmittal Letter                              |
| <input type="checkbox"/> PCT Demand (# pgs. _____)                                   | <input checked="" type="checkbox"/> Extension of Time <u>2 months</u>    |
| <input type="checkbox"/> PCT Response (# pgs. _____)                                 | <input type="checkbox"/> Express Mail No. _____                          |
| <input type="checkbox"/> PCT Amendment (# pgs. _____)                                | _____  |
|  | _____  |
|  | _____  |

MAIL STOP AMENDMENT-FEE

Rec'd in USPTO/PCT Office. Date Stamp and Return Card.

Date: 6/30/2003


Serial No.: 09/590,447; Conf. No. 1446

Title: METHODS FOR MODULATING FXR RECEPTOR.

Dkt. No.: 17302 (HL)

Enclosed Are:

- |  |  |
|--|--|
| <input type="checkbox"/> Specification # _____, Claims # _____, and Abstract # _____ | <input type="checkbox"/> Declaration, Power of Attorney                  |
| <input type="checkbox"/> Drawings (_____ sheets)<br>_____ Formal _____ Informal      | <input type="checkbox"/> Assignment & Cover Sheet                        |
| <input type="checkbox"/> Info. Disc. Statement                                       | <input checked="" type="checkbox"/> Amendment (Final) (# pgs. <u>7</u> ) |
| <input type="checkbox"/> Priority Documents # _____                                  | <input checked="" type="checkbox"/> Certificate of Mailing               |
| <input type="checkbox"/> PTO 1449 W/References                                       | <input type="checkbox"/> Issue Fee Transmittal                           |
| <input type="checkbox"/> PCT Request (# pgs. _____)                                  | <input type="checkbox"/> Transmittal Letter                              |
| <input type="checkbox"/> PCT Demand (# pgs. _____)                                   | <input type="checkbox"/> Extension of Time <u>2 months</u>               |
| <input type="checkbox"/> PCT Response (# pgs. _____)                                 | <input type="checkbox"/> Express Mail No. _____                          |
| <input type="checkbox"/> PCT Amendment (# pgs. _____)                                | _____  |
|  | _____  |
|  | _____  |



RECEIVED

JUL 15 2003

LEGAL/PATENTS



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 29 2003

CF

LEGAL PATENTS

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/590,447	06/09/2000	Barry M. Forman	17302(HL)	1446

7590

07/24/2003

Allergan Inc  
2525 Dupont Drive  
Irvine, CA 92612

EXAMINER

HUI, SAN MING R

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 07/24/2003

COPY

Please find below and/or attached an Office communication concerning this application or proceeding.

RESPONSE DUE Aug. 24, 2003

ACTION Response to  
Non-Compliant  
Amendment  
(Extensible)

RECEIVED

AUG 06 2003

TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE



AUG 06 2003

TECH CENTER 1600/2300

DEPARTMENT OF COMMERCE FOR INTELLECTUAL PROPERTY AND  
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, DC 20231  
www.uspto.gov

RECEIVED

JUL 29 2003

LEGAL/PATENTS Paper No.

## Notice of Non-Compliant Amendment (Voluntary Revised Practice)

The amendment filed July 2, 2003 under the voluntary revised amendment practice guidelines<sup>1</sup>, published in the Official Gazette on February 25, 2003 (*Amendments in a Revised Format Now Permitted*, 1267 Off. Gazette 106), does not fully comply with minimal requirements of the voluntary practice. In order for the amendment to be entered, it must either (1) comply with the guidelines of the voluntary revised amendment practice (which practice invokes waivers of certain 37 CFR 1.121(a)-(d) requirements) or (2) comply with current 37 CFR 1.121 requirements.

THE FOLLOWING ITEM(S) IN APPLICANT'S AMENDMENT CAUSES THE AMENDMENT TO BE NON-COMPLIANT WITH THE VOLUNTARY REVISED AMENDMENT PRACTICE.


- ☐ 1. A complete listing of all of the claims is not present in the amendment paper.
- ☐ 2. The listing of claims does not include the text of all claims currently under examination.
- ☐ 3. The claims of this amendment paper have not been presented in ascending numerical order.
- ☒ 4. Each claim has not been provided with a status identifier, and, as such, the individual status of each claim cannot be determined.
- ☒ 5. Other: Claims 14-30 have the wrong status identifier

LIE: Check one of the following boxes:

- ☐ **PRELIMINARY AMENDMENT:** Applicant is given ONE MONTH from the mail date of this letter to re-submit the amendment in compliance with either the guidelines of the revised amendment practice or current 37 CFR 1.121. Failure to comply with either the current 37 CFR 1.121 practice or with the voluntary practice will result in non-entry of the amendment and examination on the merits will commence without entry of the originally proposed preliminary amendment. This notice is not an action under 35 U.S.C. 132, and this ONE MONTH time limit is not extendable.
- ☒ **AMENDMENT AFTER NON-FINAL ACTION:** Since the above-mentioned reply appears to be a *bona fide* response, applicant is given a TIME PERIOD of ONE MONTH from the mailing of this notice within which to re-submit an amendment which complies with either the voluntary practice guidelines or current 37 CFR 1.121 in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD ARE AVAILABLE UNDER 37 CFR 1.136(a).

Brenda Gray  
Team Leader

<sup>1</sup> For further explanation of the guidelines of the revised amendment format, please see the posted notice and sample amendment format at:  
<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/officeflyer.pdf> and  
<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/formatrevamdtprc.pdf>



DOCKET NO: 17302(HL)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Forman et al )  
)  
Serial No.: 09/590,447 )  
Conf. No.: 1446 )  
Filed: June 9, 2000 )  
)  
For: METHODS FOR )  
MODULATING )  
FXR RECEPTOR ACTIVITY )  
)  
)  
Examiner: Hui, S. )  
)  
\_\_\_\_\_ )

Group Art Unit: 1617

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment-Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 6/30/2003

Person making Deposit: BONNIE FERGUSON

Signature: Bonnie Ferguson

Date of Signature: 6/30/2003

AMENDMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

This communication is responsive to the Office Action received January 29, 2003.  
The Office Action has been carefully considered, and Applicants have the following comments.




Serial No. : 09/590,447  
 Filed : June 9, 2000

RECEIVED 2003  
 AUG 06 2003  
 TECH CENTER 1600/2900

# AMENDMENTS AND STATUS OF CLAIMS

1. (Currently amended) A method of treating an FXR-mediated pathological condition in a mammal comprising the step of administering to a mammal in need thereof a pharmaceutically acceptable composition comprising a synthetic FXR ligand able to stimulate, block, or inhibit the activity of a mammalian FXR receptor, said synthetic FXR ligand comprising a compound of the formula



formula (3)

wherein the dashed line represents a bond or absence of a bond;

$X$  is S, O,  $NR'$  where  $R'$  is H or alkyl of 1 to 6 carbons, or

$X$  is  $(C(R_1)_2)_n$  where  $R_1$  is H or alkyl of 1 to 6 carbons, and  $n$  is an integer having the value of 0 or 1;

$R_2$  is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br, I,  $CF_3$ , fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 12 carbons, or alkylthio of 1 to 12 carbons, benzyloxy or  $C_1 - C_{12}$  alkylbenzyloxy;

$R_3$  is hydrogen, lower alkyl of 1 to 6 carbons or F;

$m$  is an integer having the value of 0 - 3;

$o$  is an integer having the value of 0 - 4 when the dashed line represents absence of a bond, and 0 - 3 when the dashed line represents a bond;

$[R_3]$   $R'_3$  is hydrogen, lower alkyl of 1 to 6 carbons, F or  $(R_{15})_r$ -phenyl,  $(R_{15})_r$ -naphthyl, or  $(R_{15})_r$ -heteroaryl where the heteroaryl group has 1 to 3 heteroatoms selected from the group consisting of O, S and N,  $r$  is an integer having the values of 0 - 5;

Serial No. : 09/590,447  
Filed : June 9, 2000

R<sub>4</sub> is alkyl of 1 to 8 carbons, or phenyl;

Y is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two R<sub>2</sub> groups;

R<sub>15</sub> is independently H, F, Cl, Br, I, NO<sub>2</sub>, N(R<sub>8</sub>)<sub>2</sub>, NH(R<sub>8</sub>), COR<sub>8</sub>, NR<sub>8</sub>CON(R<sub>8</sub>)<sub>2</sub>, OH, OCOR<sub>8</sub>, OR<sub>8</sub>, CN, an alkyl group having 1 to 10 carbons, fluoro substituted alkyl group having 1 to 10 carbons, an alkenyl group having 1 to 10 carbons and 1 to 3 double bonds, alkynyl group having 1 to 10 carbons and 1 to 3 triple bonds, or a trialkylsilyl or trialkylsilyloxy group where the alkyl groups independently have 1 to 6 carbons;

A is (CH<sub>2</sub>)<sub>q</sub> where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds;

B is hydrogen, COOH, NO<sub>2</sub>, P(O)(OH)<sub>2</sub>, P(O)(OH)OR<sub>8</sub>, P(O)(OR<sub>8</sub>)<sub>2</sub>, SO<sub>2</sub>OH, SO<sub>2</sub>(OR<sub>8</sub>), COOR<sub>8</sub>, CONR<sub>9</sub>R<sub>10</sub>, -CH<sub>2</sub>OH, CH<sub>2</sub>OR<sub>11</sub>, CH<sub>2</sub>OCOR<sub>11</sub>, CHO, CH(OR<sub>12</sub>)<sub>2</sub>, CHOR<sub>13</sub>O, -COR<sub>7</sub>, CR<sub>7</sub>(OR<sub>12</sub>)<sub>2</sub>, CR<sub>7</sub>OR<sub>13</sub>O, or tri-lower alkylsilyl, where R<sub>7</sub> is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R<sub>8</sub> is an alkyl group of 1 to 10 carbons or trimethylsilylalkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R<sub>8</sub> is phenyl or lower alkylphenyl, R<sub>9</sub> and R<sub>10</sub> independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R<sub>11</sub> is lower alkyl, phenyl or lower alkylphenyl, R<sub>12</sub> is lower alkyl, and R<sub>13</sub> is divalent alkyl radical of 2-5 carbons, or a pharmaceutically acceptable salt of said compound.

2. (Original) A method in accordance with Claim 1 where X is (C(R<sub>1</sub>)<sub>2</sub>)<sub>n</sub> and n is 1.
3. (Original) A method in accordance with Claim 1 where X is S.
4. (Original) A method in accordance with Claim 1 where X is O.
5. (Original) A method in accordance with Claim 1 where X is NR.
6. (Original) A method in accordance with Claim 1 where Y is phenyl.
7. (Original) A method in accordance with Claim 1 where Y is thienyl.

Serial No. : 09/590,447  
Filed : June 9, 2000

8. (Original) A method in accordance with Claim 1 wherein said compound has a structure selected from formulas (1) and (2).

9. (Original) A method in accordance with Claim 8 wherein said compound has a structure of formula (1) where the dashed line represents absence of a bond.

10. (Original) A method in accordance with Claim 8 wherein said compound has a structure of formula (1) where the dashed line represents a bond.


11. (Original) A method in accordance with Claim 1 wherein said compound has a structure selected from formulas (3) and (4).

12. (Original) A method in accordance with Claim 11 wherein said compound has a structure of formula (3) where the dashed line represents absence of a bond.

13. (Original) A method in accordance with Claim 11 wherein said compound has a structure of formula (3) where the dashed line represents a bond.

14-30 (Cancelled)

31. (Previously amended) A method of treating a hypercholesterolemic mammal comprising the steps: administering to a mammal in need thereof a pharmaceutically acceptable composition comprising an FXR antagonist having the following formula



formula (3)

wherein the dashed line represents a bond or absence of a bond;

X is S, O, NR' where R' is H or alkyl of 1 to 6 carbons, or  
X is (C(R1)2)n where R1 is H or alkyl of 1 to 6 carbons, and n is an integer having the value of 0 or 1;

R2 is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted

Serial No. : 09/590,447  
Filed : June 9, 2000

alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 12 carbons, or alkylthio of 1 to 12 carbons, benzyloxy or  $C_1 - C_{12}$  alkylbenzyloxy;

$R_3$  is hydrogen, lower alkyl of 1 to 6 carbons or F;

m is an integer having the value of 0 - 3;

o is an integer having the value of 0 - 4 when the dashed line represents absence of a bond, and 0 - 3 when the dashed line represents a bond;

$R'_3$  is hydrogen, lower alkyl of 1 to 6 carbons, F or  $(R_{15})_r$ -phenyl,  $(R_{15})_r$ -naphthyl, or  $(R_{15})_r$ -heteroaryl where the heteroaryl group has 1 to 3 heteroatoms selected from the group consisting of O, S and N, r is an integer having the values of 0 - 5;

$R_4$  is alkyl of 1 to 8 carbons, or phenyl;

Y is a phenyl or naphthyl group, or heteroaryl selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, imidazolyl and pyrrazolyl, said phenyl and heteroaryl groups being optionally substituted with one or two  $R_2$  groups;

$R_{15}$  is independently H, F, Cl, Br, I,  $NO_2$ ,  $N(R_8)_2$ ,  $NH(R_8)$ ,  $COR_8$ ,  $NR_8CON(R_8)_2$ , OH,  $OCOR_8$ ,  $OR_8$ , CN, an alkyl group having 1 to 10 carbons, fluoro substituted alkyl group having 1 to 10 carbons, an alkenyl group having 1 to 10 carbons and 1 to 3 double bonds, alkynyl group having 1 to 10 carbons and 1 to 3 triple bonds, or a trialkylsilyl or trialkylsilyloxy group where the alkyl groups independently have 1 to 6 carbons;

A is  $(CH_2)_q$  where q is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds;

B is hydrogen, COOH,  $NO_2$ ,  $P(O)(OH)_2$ ,  $P(O)(OH)OR_8$ ,  $P(O)(OR_8)_2$ ,  $SO_2OH$ ,  $SO_2(OR_8)$ ,  $COOR_8$ ,  $CONR_9R_{10}$ ,  $-CH_2OH$ ,  $CH_2OR_{11}$ ,  $CH_2OCOR_{11}$ , CHO,  $CH(OR_{12})_2$ ,  $CHOR_{13}O$ ,  $-COR_7$ ,  $CR_7(OR_{12})_2$ ,  $CR_7OR_{13}O$ , or tri-lower alkylsilyl, where  $R_7$  is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons,  $R_8$  is an alkyl group of 1 to 10 carbons or trimethylsilylalkyl where the alkyl group has 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or  $R_8$  is phenyl or lower alkylphenyl,  $R_9$  and  $R_{10}$  independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl,  $R_{11}$  is lower alkyl, phenyl or lower alkylphenyl,  $R_{12}$  is lower alkyl, and  $R_{13}$  is divalent alkyl radical of 2-5 carbons, or a pharmaceutically acceptable salt of said compound.

Serial No. : 09/590,447  
Filed : June 9, 2000

32. (Currently amended) A method of treating an FXR-mediated pathological condition in a mammal comprising the step of providing to said mammal a pharmaceutically acceptable composition comprising a synthetic FXR ligand able to stimulate, block, or inhibit the activity of a mammalian FXR receptor.


33. (Original) The method of claim 32 wherein said pathological condition comprises hypercholesterolemia.

34. (Original) The method of claim 32 wherein said pathological condition comprises hypocholesterolemia.

35. (Original) The method of claim 32 wherein said pathological condition is characterized by the overproduction of bile acids.

36. (Original) The method of claim 32 wherein said pathological condition is characterized by the underproduction of bile acids.

37. (Currently amended) A method of treating an FXR-mediated pathological condition in a mammal comprising the step of administering to a mammal in need thereof a pharmaceutically acceptable composition comprising a synthetic FXR ligand able to stimulate, block, or inhibit the activity of a mammalian FXR receptor, said synthetic FXR ligand having the formula



wherein R<sub>2</sub> is H or lower alkyl, R<sub>4</sub> is lower alkyl of 1 to 8 carbons and B is CH<sub>2</sub>OH or COOR<sub>8</sub> where R<sub>8</sub> is H or ethyl.

38. (Original) A method in accordance with Claim 31 where R<sub>2</sub> is H and R<sub>4</sub> is ethyl.

39. (Original) A method in accordance with Claim 32 where B is CH<sub>2</sub>OH.

40. (Original) A method in accordance with Claim 33 where B is COOR<sub>8</sub>.